| Dr Robert R Gehrke, OD | |
|
7050 S Cicero Ave, Bedford Park, IL 60638-6402 | |
| (708) 496-0680 | |
| (708) 496-0716 |
| Full Name | Dr Robert R Gehrke |
|---|---|
| Gender | Male |
| Speciality | Optometrist |
| Location | 7050 S Cicero Ave, Bedford Park, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992818694 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert R Gehrke, OD 10624 Jacob Dr, Mokena, IL 60448-9474 Ph: (708) 479-4502 | Dr Robert R Gehrke, OD 7050 S Cicero Ave, Bedford Park, IL 60638-6402 Ph: (708) 496-0680 |
News Archive
For newborn infants at risk of infection with group B streptococcal (GBS) bacteria, screening blood tests cause extra pain and anxiety—without increasing detection of early-onset GBS disease, reports a study in the October issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Scientists at Carnegie Mellon University's Molecular Biosensor and Imaging Center have developed new "fluorogen activating proteins" (FAPs) that will become a key component of novel molecular biosensor technology being created at Carnegie Mellon.
A study published in the current issue of Cell Transplantation (Vol.17, No. 8) suggests that mature adipocytes - fat cells - could become a source for cell replacement therapy to treat central nervous system disorders.
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
UNC Lineberger Comprehensive Cancer Center researchers have discovered that a deficiency in a key protein that regulates immune system warning signals could be a new biomarker for colorectal cancer, the second largest cancer killer in the United States. They believe the marker could be used to gauge response to a potential new treatment for the disease.
› Verified 6 days ago
Dr. Selma Hannoun, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 7050 S Cicero Ave, Bedford Park, IL 60638 Phone: 708-496-0680 | |
Robert Gehrke Od Optometrist Medicare: Not Enrolled in Medicare Practice Location: 7050 S Cicero Ave, Bedford Park, IL 60638 Phone: 708-496-0680 |